Marex Group’s Evolus EOLS Stock Holding History

Marex Group’s Portfolio EOLS Stock Details EOLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-76,850	Closed	-$511K	–	1095
2025 Q4	$511K	Buy	76,850 +30,000	+64%	+$203K	﹤0.01%	560
2025 Q3	$288K	Buy	+46,850	New	+$365K	﹤0.01%	634

Other funds holding EOLS

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group's EOLS Position: Q1 2026 in Review

Marex Group sold out of Evolus (EOLS) in Q1 2026, closing a stake of 76,850 shares — an estimated $511K sold.

Marex Group first reported a position in EOLS in Q3 2025 and held it in 2 quarters. The position peaked at $511K in Q4 2025. 147 funds tracked by Wall St. Rank hold EOLS as of Q1 2026.

Marex Group reported no remaining Evolus position as of Q1 2026 after selling out during the quarter.
Marex Group sold 76,850 Evolus shares in Q1 2026, an estimated $511K.
Marex Group first reported a position in Evolus in Q3 2025 and held it in 2 quarters.
Marex Group's Evolus position peaked at $511K in Q4 2025.
147 funds tracked by Wall St. Rank held Evolus as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.